- Why are the majority of Monkeypox infected people who have sex with men (MSM)?
- Experimental treatment improves skin cancer survival by 25%
- People who get flu vaccine are 40% less likely to develop Alzheimer’s disease
- Depriving women of the right to abortion is a setback for medical health and society
- 83 U.S. attorneys general pledge not to prosecute women who have abortions
- Genomic data reveal evolutionary trajectory of current monkeypox epidemic
Ono launched the 1st cancer cachexia drug: Adlumiz (anamorelin) in Japan
Ono launched the 1st cancer cachexia drug: Adlumiz (anamorelin) in Japan. The first cancer cachexia drug! Ono Pharmaceutical launched Adlumiz (anamorelin) in Japan: Effectively increase weight/muscle mass/appetite!
-Ono Pharmaceutical recently announced the launch of Adlumiz (anamorelin) 50mg tablets in Japan, which is a ghrelin receptor agonist for the treatment of non-small cell lung cancer, gastric cancer, pancreatic cancer, Cancer cachexia in patients with malignant tumors such as colorectal cancer.
It is worth mentioning that Adlumiz is the first drug to treat cancer cachexia. Clinical data shows that Adlumiz can increase body weight, muscle mass, and appetite in cancer cachexia patients. The listing of Adlumiz will provide a new treatment option for cancer cachexia patients who have no treatment in Japan and help improve the quality of life of such patients.
Cancer cachexia is a complex metabolic disorder syndrome characterized by weight loss (especially loss of muscle mass) and cancer-related anorexia. Cancer cachexia can have a great adverse effect on the quality of life and prognosis of patients. However, in Japan, no effective drugs have been approved for the treatment of cancer cachexia.
anamorelin has been rated as one of the most important innovations in the field of oncology. As cancer cachexia is still untreatable to a large extent, as the first drug to treat cancer cachexia, the launch of Adlumiz marks an important milestone in improving the quality of life of all cancer cachexia patients.
The active pharmaceutical ingredient of Adlumiz is anamorelin, which is a new, oral, selective ghrelin receptor agonist. Ghrelin is an endogenous peptide mainly secreted by the stomach. After binding to its receptor, it stimulates a variety of ways to positively regulate body weight, muscle mass, appetite and metabolism. By simulating the ghrelin secreted by the gastrointestinal tract, anamorelin can improve the weight loss and loss of appetite in cancer cachexia patients.
According to the licensing agreement signed with Helsinn Healthcare SA, a subsidiary of the Swiss Helsinn Group, Ono Pharmaceuticals has the exclusive rights to develop and commercialize anamorelin in Japan, South Korea, and Taiwan.
Adlumiz active pharmaceutical ingredient anamorelin chemical structure
Adlumiz was approved in Japan in January 2021. The approval is mainly based on the results of two clinical studies conducted in Japan for cancer cachexia patients: (1) A multicenter, placebo-controlled, randomized, double-blind, parallel group conducted in patients with non-small cell lung cancer (NSCLC) Study (ONO-7643-04 study); (2) A multi-center, open-label, uncontrolled phase III study (ONO-7643-05 study) in patients with colorectal cancer, gastric cancer, and pancreatic cancer.
In these studies, Adlumiz was shown to increase body weight, muscle mass, and appetite in cancer patients with cachexia.
(source:internet, reference only)